top of page
News
Search
iQure Pharma Secures $4M Funding – Advancing Phase 1 Clinical Trial for iQ-007
Princeton, NJ, January 07, 2025 ─  iQure Pharma Inc. (iQure), a biotechnology company focused on the development of novel therapies for...
Jan 7
Initial iQ-007 IND-Enabling Tox Results Accelerate Prep for First in Human Phase 1 Study
Princeton, NJ, March 19, 2024 ─ iQure Pharma Inc. (iQure), a US-based global biotech, announced that its asset, iQ-007, a novel...
Mar 19, 2024
iQure Pharma Awarded Its First Patent for iQ-008, a Novel Analgesic Compound to Treat Neuropathic Pain
Princeton, NJ, January 23, 2024 ─ iQure Pharma Inc. (iQure), a US-based global biotech, announced that its asset, iQ-008, a novel...
Jan 23, 2024
iQure Pharma Attending JPM Week in San Francisco — January 8-12, 2024
Princeton, NJ, December 22, 2023 ─ iQure Pharma Inc. (iQure), a U.S.-based pre-clinical drug discovery company focusing on central...
Dec 22, 2023
JPM Week
No Abuse
bottom of page